Imiglucerase

Imiglucerase Brand Name– Cerezyme

What is Imiglucerase

Imiglucerase is parenteral enzyme used in the treatment of patients with Gaucher’s disease.

Imiglucerase replaces the endogenous enzyme beta-glucocerebrosidase.

Imiglucerase is produced by recombinant DNA technology using Chinese hamster ovary cell cultures and differs from the endogenous enzyme by one amino acid at position 495 where histidine is substituted for arginine.

Imiglucerase was approved by the FDA in March 1994. A related product, alglucerase (Ceredase®), produced from pooled human placental tissue from selected donors, was approved April 1991.

Indications

  • Gaucher disease

For enzyme replacement therapy in patients with confirmed Gaucher disease type 1 (GD1) who have at least one of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly

Side Effects

  1. abdominal pain
  2. anaphylactoid reactions
  3. angioedema
  4. antibody formation
  5. chest pain (unspecified)
  6. chills
  7. cough
  8. cyanosis
  9. diarrhea
  10. dizziness
  11. dyspnea
  12. fatigue
  13. fever
  14. flushing
  15. headache
  16. hypotension
  17. injection site reaction
  18. nausea
  19. peripheral edema
  20. pruritus
  21. rash
  22. sinus tachycardia
  23. urticaria
  24. vomiting

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • breast-feeding
  • gelatin hypersensitivity
  • pregnancy
  • pulmonary hypertension

Interactions

  • Miglustat

Miglustat: (Major) Combination therapy with miglustat and imiglucerase is not indicated for Gaucher disease. Miglustat may increase the clearance of imiglucerase, although the clinical significance of this interaction is not yet known. 

You cannot copy content of this page